News

Valneva announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Dr. Stanley A. Plotkin, MD and Dr. Anna…

05 Dec'19

Valneva announced today that its management team including Thomas Lingelbach, CEO, David Lawrence, CFO, and Franck Grimaud, CBO, will hold media,…

04 Dec'19

The highly collaborative environment of the Vienna BioCenter is once again demonstrated by three new Special Research Programmes (SFBs) going to…

03 Dec'19

Interdisciplinary panel discussion. ©Paul Pipernig

On December 2nd, a large-scale public event, organized by the City of Vienna in cooperation with the Vienna BioCenter took place in the Globe Theater.…

28 Nov'19

Multidrug resistance (MDR) is a fundamentally important medical phenomenon that undermines anticancer and anti-infective therapy of cancer or…

28 Nov'19

Valneva announced that the European Medicines Agency (EMA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO^® f…

28 Nov'19

Researchers in Vienna from Ulrich Elling’s laboratory at IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences – in…

27 Nov'19

Successful collaboration of research and industrial members of Vienna BioCenter awarded by the Austrian Research Promotion Agency (FFG) in the form of…

27 Nov'19

The prize was awarded for Ares Genetics’ ARESupa –Universal Pathogenome Assay, a diagnostic toolfor personalized antibiotic resistance diagnostics…

22 Nov'19

New insights into the process of DNA-looping change our view of how the genome is organised within cells. The discoveries by IMP-researchers now…

18 Nov'19

Valneva announced excellent final Phase 1 results for its single-shot chikungunya vaccine candidate, VLA1553.

14 Nov'19

Valneva announced the appointment of two leading vaccine experts to its Scientific Advisory Board (SAB). Dr. Norman W. Baylor, PhD, and Dr. George R.…

Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board

Valneva to Conduct Investor and Partnering Meetings during the 38th Annual J.P. Morgan Healthcare Conference

Three Special Research Programme grants for Vienna BioCenter scientists

A large-scale public event bridging science and society

Putting a Lid on Multidrug Resistance

Valneva Announces EMA Approval of IXIARO® Shelf Life Extension to 36 Months

Harnessing the power of CRISPR in space and time

“Innovation Voucher” for Haplogen and the Metabolomics unit of the VBCF

Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize

IMP researchers show that cohesin is a "molecular machine"

Valneva Reports Excellent Final Phase 1 Results for its Chikungunya Vaccine Candidate, Confirms Plans

Valneva Announces Appointments of Two Leading Vaccine Experts to its Scientific Advisory Board